GeneDx Holdings (WGS) Revenue (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Revenue data on file, last reported at $102.3 million in Q1 2026.

• Revenue for Q1 2026 came in at $102.3 million, up 17.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $442.7 million (up 34.09% YoY), and the FY2025 annual result was $427.5 million, up 39.97% from the prior year.
• Revenue declined to $102.3 million in Q1 2026 per WGS's latest filing, from $121.0 million in the prior quarter.
• Over five years, Revenue peaked at $121.0 million in Q4 2025 and troughed at $36.2 million in Q2 2022.
• A 5-year average of $74.9 million and a median of $70.5 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue soared 92.77% in 2022, then sank 35.96% in 2023.
• A 5-year view of Revenue shows it stood at $61.4 million in 2022, then declined by 6.41% to $57.4 million in 2023, then surged by 66.57% to $95.6 million in 2024, then advanced by 26.5% to $121.0 million in 2025, then decreased by 15.48% to $102.3 million in 2026.
• Business Quant data shows WGS's Revenue at $102.3 million in Q1 2026, $121.0 million in Q4 2025, and $116.7 million in Q3 2025.